Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics Inc. focuses on clinical research in facioscapulohumeral muscular dystrophy, with studies centered on disease progression, muscle function, and long-term treatment effects in affected individuals.
- FSHD
- Muscle weakness
- Functional outcomes
The company’s research activity in this area is directed toward understanding and addressing the clinical burden of this inherited neuromuscular disorder.
FSHD1
Clinical trials also concentrate on FSHD1, examining safety, tolerability, and sustained treatment use in this genetic subtype of facioscapulohumeral muscular dystrophy.
- Genetic muscle disease
- Long-term tolerability
- Subtype-specific research
This area reflects a targeted interest in the clinical management of patients with the most common form of the disorder.
Neuromuscular disease assessment
The sponsor’s studies include evaluation of clinical outcome measures relevant to muscle performance, physical impairment, and progression of neuromuscular disease.
- Muscle performance
- Disease progression
- Patient function
These research efforts support a detailed focus on measurable changes in strength and daily physical capability.
Long-term safety and tolerability
Fulcrum Therapeutics maintains a research interest in the extended use of treatments for FSHD and FSHD1, with emphasis on ongoing safety monitoring and treatment tolerability.
- Safety monitoring
- Treatment tolerability
- Extended treatment use
This domain is closely tied to chronic disease care, where sustained management is central to clinical research priorities.
